IN2015DN00091A - - Google Patents

Download PDF

Info

Publication number
IN2015DN00091A
IN2015DN00091A IN91DEN2015A IN2015DN00091A IN 2015DN00091 A IN2015DN00091 A IN 2015DN00091A IN 91DEN2015 A IN91DEN2015 A IN 91DEN2015A IN 2015DN00091 A IN2015DN00091 A IN 2015DN00091A
Authority
IN
India
Prior art keywords
antigens
present
antigen binding
species
target
Prior art date
Application number
Other languages
English (en)
Inventor
Haard Johannes Joseph Wilhelmus De
Christophe Frederic Jerome Blanchetot
Original Assignee
Argen X Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Argen X Bv filed Critical Argen X Bv
Publication of IN2015DN00091A publication Critical patent/IN2015DN00091A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/18—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns
    • B01D15/1864—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IN91DEN2015 2012-07-20 2013-07-19 IN2015DN00091A (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1212940.9A GB2504139B (en) 2012-07-20 2012-07-20 Antibodies to highly conserved targets produced by the immunisation of Camelidae species
PCT/EP2013/065350 WO2014013075A2 (en) 2012-07-20 2013-07-19 Antibodies to highly conserved targets

Publications (1)

Publication Number Publication Date
IN2015DN00091A true IN2015DN00091A (enExample) 2015-05-29

Family

ID=46881721

Family Applications (1)

Application Number Title Priority Date Filing Date
IN91DEN2015 IN2015DN00091A (enExample) 2012-07-20 2013-07-19

Country Status (10)

Country Link
US (2) US20150191548A1 (enExample)
EP (1) EP2875048A2 (enExample)
JP (1) JP2015524404A (enExample)
CN (1) CN104520317A (enExample)
AU (1) AU2013291937A1 (enExample)
CA (1) CA2877446A1 (enExample)
GB (1) GB2504139B (enExample)
IL (1) IL236525A0 (enExample)
IN (1) IN2015DN00091A (enExample)
WO (2) WO2013064701A2 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
CN103025884B (zh) 2010-07-26 2015-11-25 特里安尼公司 转基因动物和使用方法
US10793829B2 (en) 2010-07-26 2020-10-06 Trianni, Inc. Transgenic mammals and methods of use thereof
BR112013021562B1 (pt) * 2011-03-16 2023-01-10 Argenx Bvba Anticorpos para cd70
US20160251440A1 (en) * 2013-09-26 2016-09-01 Ablynx N.V. Bispecific nanobodies
GB201414823D0 (en) 2014-08-20 2014-10-01 Argen X Bv Multispecific antibodies
KR20170136536A (ko) * 2015-03-16 2017-12-11 셀덱스 쎄라퓨틱스, 인크. 항-met 항체 및 그 사용 방법
WO2016156468A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptides
EP3277719B1 (en) 2015-03-31 2022-03-16 Sorriso Pharmaceuticals, Inc. Polypeptides
EP3277706A1 (en) 2015-03-31 2018-02-07 VHsquared Limited Polypeptide comprising an immunoglobulin chain variable domain which binds to clostridium difficile toxin b
WO2016156474A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptide comprising an immunoglobulin chain variable domain which binds to clostridium difficile toxin a
AU2016239949A1 (en) 2015-03-31 2017-09-07 Sorriso Pharmaceuticals, Inc. Peptide construct having a protease-cleavable linker
EP3294775B1 (en) 2015-05-12 2021-07-14 Regeneron Pharmaceuticals, Inc. Multimeric protein purity determination
EP3384030A4 (en) 2015-12-03 2019-07-03 Trianni, Inc. IMPROVED IMMUNOGLULINIVITY
EP4414484A3 (en) 2016-02-04 2025-01-15 Trianni, Inc. Enhanced production of immunoglobulins
GB201612337D0 (en) 2016-07-15 2016-08-31 Argen-X N V Ant-il-22r antibodies
WO2018060453A1 (en) 2016-09-30 2018-04-05 Vhsquared Limited Compositions
TWI782930B (zh) * 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
CN110139952B (zh) * 2016-12-09 2022-11-25 深圳华大生命科学研究院 骆驼科抗体可变区免疫组库构建的引物组合及应用
CN111448217A (zh) 2017-12-22 2020-07-24 阿根思公司 双特异性抗原结合构建体
GB201802487D0 (en) 2018-02-15 2018-04-04 Argenx Bvba Cytokine combination therapy
US12570736B2 (en) 2019-06-21 2026-03-10 Sorriso Pharmaceuticals, Inc. Compositions
JP7692844B2 (ja) 2019-06-21 2025-06-16 ソリッソ ファーマシューティカルズ，インク． ポリペプチド
CA3144566A1 (en) 2019-06-21 2020-12-24 Sorriso Pharmaceuticals, Inc. Polypeptides
CN114340684B (zh) 2019-09-16 2025-09-12 瑞泽恩制药公司 用于免疫pet成像的放射性标记的met结合蛋白
WO2024039920A1 (en) * 2022-08-15 2024-02-22 Mbrace Therapeutics, Inc. Cell-free methods of producing antibodies to intracellular targets
AU2023364731A1 (en) 2022-10-21 2025-04-03 Diagonal Therapeutics Inc. Heteromeric agonistic antibodies to il-18 receptor
CN121057752A (zh) 2023-04-07 2025-12-02 达科纳治疗有限公司 铰链经修饰的双特异性抗体
US20250002588A1 (en) 2023-04-07 2025-01-02 Diagonal Therapeutics Inc. Bispecific agonistic antibodies to activin a receptor like type 1 (alk1)
WO2024243048A1 (en) 2023-05-19 2024-11-28 Diagonal Therapeutics Inc. Bispecific agonistic antibodies to il12 receptor
IL327756A (en) 2023-10-23 2026-06-01 Diagonal Therapeutics Inc Heteromeric agonistic antibodies to il-18 receptor
WO2025213061A2 (en) 2024-04-04 2025-10-09 Ethyreal Bio, Inc. Anti-tshr antibodies and uses thereof
WO2026044000A1 (en) 2024-08-20 2026-02-26 Ethyreal Bio, Inc. Multispecific antibodies and methods of use thereof
WO2026080752A2 (en) 2024-10-09 2026-04-16 Diagonal Therapeutics Inc. De novo antibodies to activin a receptor like type 1 (alk1)
WO2026080757A2 (en) 2024-10-09 2026-04-16 Diagonal Therapeutics Inc. Activin receptor type ii a/b (actriia/b) antibodies
US20260234273A1 (en) 2024-10-09 2026-08-13 Diagonal Therapeutics Inc. Bone morphogenetic protein receptor type 2 (bmprii) antibodies
WO2026102148A1 (en) 2024-11-07 2026-05-15 Diagonal Therapeutics Inc. Alk1 / bmprii bispecific antibodies for treatment of ocular diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
JP3683278B2 (ja) * 1995-12-20 2005-08-17 ザ ユニバーシティ オブ ケンタッキー リサーチ ファウンデーション マウスモノクローナル抗イディオタイプ抗体１１ｄ１０およびその使用方法
AU2004272607B2 (en) * 2003-09-11 2008-11-06 Cornerstone Therapeutics Inc. Monoclonal antibodies against HMGB1
JP2008520552A (ja) * 2004-10-22 2008-06-19 メディミューン，インコーポレーテッド Ｈｍｇｂ１に対する高親和性の抗体およびその使用法
IL198545A0 (en) 2008-05-14 2011-07-31 Metheresis Translational Res Sa High affinity binding site of hgfr and methods for identification of antagonists thereof
GB2461546B (en) * 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
US8444976B2 (en) * 2008-07-02 2013-05-21 Argen-X B.V. Antigen binding polypeptides
CN102361884A (zh) 2009-04-07 2012-02-22 罗氏格黎卡特股份公司 双特异性抗-ErbB-2/抗-c-Met抗体
ME02637B (me) * 2010-08-20 2017-06-20 Novartis Ag Antitela za receptor 3 faktora rasta epiderma (her3)

Also Published As

Publication number Publication date
CA2877446A1 (en) 2014-01-23
GB201212940D0 (en) 2012-09-05
IL236525A0 (en) 2015-02-26
WO2014013075A2 (en) 2014-01-23
WO2014013075A3 (en) 2014-12-18
US20180016351A1 (en) 2018-01-18
JP2015524404A (ja) 2015-08-24
US20150191548A1 (en) 2015-07-09
GB2504139B (en) 2014-12-31
CN104520317A (zh) 2015-04-15
WO2013064701A3 (en) 2013-07-18
EP2875048A2 (en) 2015-05-27
WO2013064701A2 (en) 2013-05-10
AU2013291937A1 (en) 2015-01-22
GB2504139A (en) 2014-01-22

Similar Documents

Publication Publication Date Title
GB201212940D0 (en) Antibodies to highly conserved targets
AU2018260863A1 (en) Human IgG1 Fc region variants and uses thereof
PH12018501611A1 (en) Antigen binding proteins thant bind pd-l1
BR112013021562A2 (pt) anticorpos para cd70
IN2014CN00807A (enExample)
MX341309B (es) Anticuerpos especificos del heterodimero de anti-il-23.
PH12014502527B1 (en) St2 antigen binding proteins
EA201200195A1 (ru) АНТИТЕЛА ПРОТИВ ЭКТОДОМЕНА ErbB3 И ИХ ПРИМЕНЕНИЕ
EA201591407A1 (ru) Антитела, содержащие химерные константные домены
MX2017001401A (es) Constructos de anticuerpos de cadena sencilla biespecifica especificos para especies cruzadas optimizadas.
BR112015022123A8 (pt) Anticorpos, fragmentos de ligação ao antígeno dos mesmos que se ligam especificamente à hepcidina ou um peptídeo de hepcidina, uso, meio contentor e kit
WO2014059442A3 (en) Antibody based reagents that specifically recognize toxic oligomeric forms of tau
EA201270813A1 (ru) АНТИТЕЛА К N3pGlu БЕТА-АМИЛОИДНОМУ ПЕПТИДУ И ИХ ПРИМЕНЕНИЕ
EA202190266A1 (ru) Рекомбинантные захватывающие белки клеточной поверхности
WO2012156532A8 (en) Anti-human-her3 antibodies and uses thereof
EA201591113A1 (ru) Антитела против антигена 2 дендритных клеток крови и их применение
HK1207654A1 (en) Modified antibody regions and uses thereof
MX352117B (es) Anticuerpo anti-idiotipo dirigido contra un anticuerpo dirigido contra el peptido beta amiloideo.
EA201291065A1 (ru) Антитела против vla-4
IN2012DN03338A (enExample)
PH12015500752A1 (en) Her3 antigen binding proteins binding to the beta-hairpin of her3
IN2014MN01868A (enExample)
WO2013064700A3 (en) Chimeric human-camel antigens and their use
PH12016501579B1 (en) Novel anti-presepsin antibody
WO2014151834A3 (en) Methods and compositions relating to anti-ccr7 antigen binding proteins